Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment symbols : AGNPF save search
Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast
Published: 2023-11-08 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.0608 178.69% 3.2K
|
Health Technology
|
| O: -8.27%
H: 0.0%
C: 0.0%
patent treatment pharmaceuticals nash
Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD
Published: 2023-05-31 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0608 178.69% 3.2K
|
Health Technology
|
| O: -4.89%
H: 0.0%
C: 0.0%
patent treatment pharmaceuticals
Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil Ifenprodil Represents a Novel First-in-Class Potential Treatment for Chronic Cough
Published: 2023-01-09 (Crawled : 21:00) - biospace.com/
AGNPF | $0.0608 178.69% 3.2K
|
Health Technology
|
| O: -4.07%
H: 0.0%
C: 0.0%
treatment pharmaceuticals potential study phase 2b
Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
Published: 2022-12-05 (Crawled : 19:00) - biospace.com/
AGNPF | $0.0608 178.69% 3.2K
|
Health Technology
|
| O: 21.05%
H: 0.0%
C: -4.78%
treatment fda fibrosis pharmaceuticals designation drug
Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF
Published: 2022-09-19 (Crawled : 12:00) - biospace.com/
AGNPF | $0.0608 178.69% 3.2K
|
Health Technology
|
| O: -3.64%
H: 4.85%
C: 4.85%
treatment fda designation
Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
Published: 2022-06-22 (Crawled : 14:00) - biospace.com/
AGNPF | $0.0608 178.69% 3.2K
|
Health Technology
|
| O: 34.22%
H: 0.0%
C: 0.0%
treatment fibrosis patent
Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study
Published: 2021-11-01 (Crawled : 19:00) - biospace.com/
AGNPF | $0.0608 178.69% 3.2K
|
Health Technology
|
| O: -4.6%
H: 5.49%
C: 4.83%
treatment
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.